3 Crucial Things to Know About Moderna Right Now
During the earlier days of the pandemic, it was easy to see why Moderna (NASDAQ: MRNA) made for a great investment. The company took leadership in the vaccine race right from the start. And once Moderna launched its vaccine, it dominated the market along with rival Pfizer. The vaccine has generated billions in earnings for Moderna -- and helped it build up a massive cash level.
But as we head toward a post-pandemic world, you may be wondering if Moderna still makes a good investment. After all, it relies on the coronavirus vaccine and booster for all of its product revenue. And vaccine demand is on the decline. Before deciding whether or not to buy this vaccine giant, here are three crucial things to know.
The year 2023 isn't likely to be Moderna's biggest when it comes to earnings growth. But that's OK. We've seen this coming, and it doesn't mean growth is over. This is a transition year. We're shifting to a post-pandemic environment, and that means a few different things.
Source Fool.com
